Many questions about the long-term effects of combination antiretroviral therapy (cART) on clinical outcomes in people living with HIV (PLWH) and their impact on health systems remain unanswered. The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) was formed in 2005 to pool and harmonize existing longitudinal data on people living with HIV in Europe, to answer key research questions that could not be addressed adequately by individual cohorts. Key research questions include long-term prognosis, rare outcomes, and variations across patient groups, settings and health systems. COHERE uses the HIV Cohorts Data Exchange Protocol, a standardized and validated method of data structure and transfer, to compile data from over 40 cohorts of PLWH residing in Europe, representing 331 481 individuals, including 2808 children (<13), representing 2 135 896 person-years of follow-up. COHERE compiles data on clinical characteristics, antiretroviral therapy and other medications, estimated date of HIV seroconversion, opportunistic infections, laboratory results and socio demographic data.
• Non-injection drug users living with HIV with CD4 cell counts above 500/mm 3 after starting cART had mortality patterns similar to those in the general population.
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Who participates in COHERE?
COHERE has grown from 33 cohorts in 2005 to 40 in 2015. COHERE initially approached cohorts because of their proven ability to address scientific questions and collect good quality data at clinical sites. As COHERE is a project-based collaboration, the data pooled in annual mergers depend on the projects included. Western European countries with longstanding national cohorts contribute a large proportion of person-years of follow-up, but there is an increasing number of individuals in care in Eastern Europe, primarily via the EuroSIDA network. 5 Figure 1 presents the number of people living with HIV (excluding deaths) included in COHERE as of 31/12/2011 as a percentage of UNAIDS 2011 estimates of people living with HIV by country. COHERE includes both clinic/hospital-based cohorts of HIV-infected individuals, where data are extracted primarily from medical records in the context of routine care, and interval cohorts of specific populations of HIV-infected people, where data are collected at regular intervals that are unrelated to participants ongoing health care. Since people with HIV are seen regularly over a long period of time at a clinic/hospital, and are not just attending at times when they are symptomatic, the group of people seen at a given hospital naturally Page 6 of 29   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 (Table 2a ). Of those with an available CD4 cell counts at enrolment, 29% had <200 cells/mm 3 , 22% had between 200 and 350 cells/mm 3 , and 49% had >350 cells/mm 3 . Of those younger than age 13 (N=2808, representing 23 458), 93.7% were infected via vertical transmission and 73.4% had never had an AIDS diagnosis (Table 2b ).
How often have they been followed up?
As a consortium of cohorts comprising clinic and interval cohorts, patient follow-up varies.
For clinic or hospital-based cohorts, average patient follow-up reflects current standards of care in those countries.
A derived measure of lost to follow-up (LTFU) was constructed by estimating the median last clinical encounter (defined as either visit and/or the date of last laboratory test) per active cohort. Those individuals who had not had a clinical encounter in the 18-months prior to this date were considered to be LTFU. Those who died during the same period were excluded.
On average, 25% of the COHERE 2014 sample met this definition of LTFU, with variation between cohorts. LTFU in paediatric cohorts was estimated among those under age 17 as Page 7 of 29   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 ultimately improving data quality with each merger. To ensure transparency, the content of each merger together with cohort's QA check feedback is summarized in a report. DMs extract data for projects based on specified and agreed eligibility criteria. After signing a data protection agreement, project leads are sent data extractions in a secure format.
What has been found?
Projects within the COHERE collaboration have led to the publication of 28 articles in peerreviewed journals as of April, 2016, contributing high-quality evidence that has informed clinical and public health decision-making.
Prognosis and the effect of ART
The "Prognosis and the effect of ART" group focuses on clinical outcomes in patients treated with cART. The effect of age on the response to cART was studied in around 50,000 antiretroviral-naive individuals. Older individuals were characterized by low pre-ART CD4 cell counts, and experienced poorer immunological responses but better virologic responses, indicating those who are diagnosed or treated late are at increased risk of clinical events. 8
Non-IDU HIV-infected individuals who achieved high CD4 cell counts after starting cART were found to have mortality patterns similar to those in the general population. Mortality was found to be persistently higher in individuals with a prior AIDS diagnosis 9 , while the incidence of AIDS events continued to decline until CD4 cell counts were greater than 750 cells/mm 3 . 10 In patients with viral suppression, the risk of a new AIDS events or death followed a CD4 cell count gradient, even benefiting those with a CD4 cell count ≥500 cells/mm 3 . 11 Individuals who were virally suppressed on cART for more than three years but had incomplete CD4 cell recovery experienced substantially higher rates of mortality from both AIDS and non-AIDS causes, suggesting that these individuals should be monitored for diseases not conventionally considered HIV-related, especially non-AIDS defining cancers Page 9 of 29   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 10 and liver diseases. 12 Future research will focus on new markers of the risk of morbidity and cause-specific mortality, outcomes in individuals treated for many years, and outcomes in people aging with HIV, particularly in the context of multi-morbidity and polypharmacy.
The COHERE's Pursuing Later Treatment Options (PLATO) II project looked at the rate of development of virologic failure in adults, adolescents and children. When virologic failure has occurred with at least two nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), a non-nucleoside reverse transcriptase inhibitor (NNRTI) and a ritonavir-boosted protease inhibitor (PI), patients are said to have experienced triple class virologic failure (TCVF).
Fewer than 9% of adult patients had experienced TCVF at year nine after starting cART. 13 The risk of TCVF was somewhat higher in children and particularly higher in adolescents. 14 
Virologic suppression after TCVF was found to have increased from 20% in 2000 to 58% in
2009. Rates of AIDS and death also declined over time in people with TCVF. 15 The incidence of TCVF in people on cART declined after 2008, and prevalence stabilized at around 2.5%. 16 An approximately linear inverse relationship between log 10 viral load and CD4 cell count in people with TCVF points to likely immunologic benefits of reducing viral load, even by modest amounts, without necessarily resulting in an undetectable viral load. 17
Late Presentation
Late presentation is defined as an HIV-diagnosis with a CD4 cell count <350/mm 3 or an AIDS 2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 11 different regions and demographic groups since 2010. 19 These findings have provided comprehensive evidence of patterns in late presentation in Europe and have informed discussions around earlier and more widespread testing for HIV and linkage to HIV care. 20
Opportunistic Infections
Thirty per cent of HIV infected people either present late with an OI or are at significant risk of an OI. 18 The COHERE OI group has described both the spectrum and incidence of OIs in patients on cART with high CD4 cell counts. 10, 11 By including viral suppression as a cofactor, it was found that Pneumocystis jirovecii prophylaxis could safely be stopped in an additional 40% of patients when compared with guidelines based exclusively on CD4 cell counts, 21 findings which informed both the American and European treatment guidelines 22, 23 . The group is conducting similar analyses for toxoplasmosis and other OIs and intends to reassess the guidelines on the timing for discontinuing secondary prophylaxes against specific OIs.
While the early start of cART in the course of cryptococcal meningitis has been shown to be harmful in some clinical trials performed in resource-limited settings 24, 25 , in Western settings with advanced clinical monitoring this may not be the case. 26 Current COHERE projects are examining the effect on mortality of the time of cART initiation after a diagnosis of cryptococcal meningitis or Toxoplasma gondii encephalitis. Preliminary results from a COHERE, NA-ACCORD and CNICS collaboration have shown that early cART did not increase mortality in AIDS patients with cryptococcal meningitis in high-income countries and overall mortality was lower than that reported by the clinical trials conducted in Africa. 27 Current analyses explore how specific OIs influence long-term immune reconstitution, morbidity and mortality in the most recent cART era. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 12 The COHERE malignancy group has focused on defining the incidence, risk factors and prognosis of HIV-associated cancers in the cART era, with a focus on systemic non-Hodgkin lymphoma (NHL) and primary brain lymphoma (PBL), Hodgkin's lymphoma and, more recently, Kaposi's sarcoma. [28] [29] [30] The incidence of non-Hodgkin's lymphoma, primary brain lymphoma and Kaposi's sarcoma were substantially reduced in patients on cART, and timely initiation of therapy at high CD4 cell counts is important for preventing these malignancies. 28, 30 In contrast, the incidence of Hodgkin's lymphoma was not reduced by cART. Patients whose CD4 cell counts declined despite suppression of HIV-1 replication on cART were at increased risk of Hodgkin's lymphoma. 29 Comparative analyses are planned in collaboration with the African regions of IeDEA. 4
Malignancy
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Hepatitis
The immunological changes over the course of HCV treatment and their effect on mortality were estimated in 6,433 HIV-HCV-co-infected adults (≥16), 12% of whom had initiated HCV treatment (n=692 interferon and ribavirin; n=88 interferon alone). 31 CD4 cell counts decreased over the first 12 weeks but stabilized from week 24 onwards with no negative impact on mortality. The group is poised to monitor the effect of the introduction of directacting antiviral agents in co-infected patients.
Socio-economic inequalities
The Socio-economic inequalities group studies differences in key outcomes by sex, race/ethnicity, migrant status and educational level as a proxy for socioeconomic position.
Even in European countries with universal health care systems, it has been documented that individuals with lower educational level do not benefit equally from timely cART initiation and have a poorer response to cART. 32 Mortality in migrants has been found to be lower compared to native populations, which has been attributed to the "healthy migrant effect". COHERE's larger sample size has allowed Page 12 of 29   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 13 this group to study mortality in men and women from multiple geographical origins separately, highlighting heterogeneity among migrant groups and revealing how certain groups are at an increased risk of mortality 33 , work which was featured in the first issue of UNAIDS Science Now. The group plans to examine differences in cause-specific mortality by country of origin.
What are the main strengths and weaknesses?
COHERE in EuroCoord's infrastructure is a unique research platform which has prompted collaborations both within and beyond Europe. EuroCoord's cross-network work packages on data capture, HIV tuberculosis, migrant health and modelling and its interdisciplinary working groups (clinicians, virologists, epidemiologists, biostatisticians) have formalized this cross network collaboration and fostered intra-European capacity building. COHERE's further investment in data harmonization (HICDEP) has benefitted other regional collaborations.
Efforts to streamline data submission with the CASCADE and ART-CC cohort collaborations improved efficiency and reduced the workload of DMs. Finally, COHERE has provided excellent training opportunities for junior researchers (PhDs and Fellowships).
COHERE's greatest strength is its size, enabling stratification of subgroups of interest 8 (e.g. across 10 age groups and sex-stratification) and the study of uncommon outcomes. 28 The robustness of COHERE's findings transcends Europe, benefiting the global HIV-patient community. COHERE data are highly representative of those in care in countries with large regional and national cohorts. Such cohorts enable COHERE to monitor trends across countries. However, adequate representation of marginalized groups such as migrant populations has become a challenge as a consequence of informed consent requirements in some countries as well as barriers to accessing care. 34 Although COHERE uses HICDEP, the heterogeneity in data quality remains an ongoing challenge. In collaboration with ART-CC 3 , COHERE has been an ideal platform for harmonizing the collection and validation of causes of deaths in HIV-1 infected individuals. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 
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Conclusion
COHERE is now a mature collaboration, which is unique in its size and coverage. It continues to produce new evidence on clinical outcomes, particularly AIDS-defining complications, late presentation and socio-economic inequalities, which inform clinical guidelines and public health policy recommendations. As PLWH live longer with a chronic infection, comparisons between them and cohorts of uninfected individuals are needed to disentangle the role of HIV infection from its long-term treatment and comorbidities, especially those linked to ageing.
Profile in a nutshell
• The Collaboration of Observational HIV Epidemiological Research Europe (COHERE)
is a project-driven cohort consortium that was set-up to address scientific questions that could not be addressed by single cohorts because of sample size requirements. 2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 16 • As a consortium of cohorts comprising clinic/hospital-based and interval cohorts, the frequency of patient follow-up varies. For clinic or hospital-based cohorts, average patient follow-up reflects current standards of care in those countries.
• COHERE compiles data on clinical characteristics, antiretroviral therapy and other medications, estimated date of HIV seroconversion, opportunistic infections, laboratory results and socio demographic data according to the requirements of projects.
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Design and Measures:
COHERE is a cohort consortium that compiles data from 40 diverse cohorts of PLWH in Europe annually. The specific data merged is dictated by the eligibility criteria for included projects. Data categories commonly include clinical characteristics, antiretroviral therapy and other medications, estimated date of HIV seroconversion, opportunistic infections, laboratory results and socio demographic data.
Unique features : The submission of data to COHERE is facilitated by the use of the HIV Cohorts Data Exchange Protocol (HICDEP), a flexible data structure, developed in 2004, to guide the mapping of individual cohort data into a standard format to facilitate data merging, and the HIV Distributed Data Management Tool (http://www.hivddm.net/). A series of quality assurance checks are conducted centrally and cohorts address data inconsistencies before data are merged. Likely duplicate patient records between and within cohorts are identified using probability linkage and reconciled.
Reasons to be cautious : Although COHERE uses HICDEP, the heterogeneity in data quality remains a challenge. With a growing proportion of deaths in PLVH are caused by non-AIDS events, accurately monitoring these causes is key to identifying trends and evaluating risk factors. The "Coding Causes of Death in HIV" Protocol (CoDe), a uniform classification system for collecting and validating data on causes of death and contributing factors in HIV-1 infected patients is being implemented.
Collaboration and data access : External collaborators interested in conducting a project in COHERE should submit a proposal to the Regional Coordinating Centres for review by COHERE's governing bodies (see www.cohere.org).
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